~~<i id='0810212B0B'><strike id='0810212B0B'><tt id='0810212B0B'><pre id='0810212B0B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：leisure time 2025-09-29 21:23:26 - browse：312

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

explore

hotspot

Wikipedia

focus

knowledge

hotspot

UnitedHealthGroupCEOAndrewWittysaidthecompanywasbeginningtoseea“disturbance”initsMedicaidmedicalcost

WSS

Philips to halt sales of sleep apnea machines in U.S.

Bernie Sanders is gearing up to subpoena pharma CEOs

Reconstructing family trees of blood cells may help predict disease

FTC loses bid to block Novant's North Carolina hospital merger

An outdated Medicare rule harms dementia patients with anxiety

Boston competes with Raleigh

focus

hotspot

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves Moderna’s RSV vaccine, its second licensed product

As demand for Covid shots wanes, Moderna seeks its next success

The Affordable Care Act has saved billions in health care costs

Duchenne breakthrough therapy leaves behind pioneering families

Elevance PBM president out as customers face prescription chaos

United colonoscopy coverage change 'may cost lives,' doctors say

How CO2 helps viruses stay alive longer in the air

Affirmative action in medical school literally saved lives

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

hotspot

CMS got Medicare Advantage quality rating wrong, judge rules

How generative AI ratchets up security threats for health systems

Zyn nicotine pouches become unlikely player in latest culture war

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

For pregnant people, addiction treatment shouldn't mean a call to child protective services

An outdated Medicare rule harms dementia patients with anxiety

Wikipedia

focus

knowledge

hotspot